Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare haematology Read more
Pfizer to discontinue development programme for PF-07265803 for LMNA-related dilated cardiomyopathy Read more
US FDA grants fast track designation to Pfizer’s ervogastat/clesacostat combination to treat NASH Read more